GPBAR1 and digestive system neoplasm: CYSLTR1 is expressed in LSECs and monocytes, and its inhibition in conjunction with a G protein-coupled bile acid receptor 1 (GPBAR1) agonist potently reverses LSEC/monocyte interactions and reduces liver damage [325].